Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib with Radiotherapy in Head and Neck Cancer
NCT02229656Phase 1Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2014
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of olaparib in laryngeal squamous cell carcinoma (LSCC) and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Incidence of Dose Limiting Toxicities at 1 year. Status: unknown.
02
Drugs
olaparib
03
Conditions
laryngeal squamous cell carcinoma (LSCC)oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT02229656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229656.